Nasdaq Blrx News Today

StockNews.com upgraded shares of BioLineRx (NASDAQ:BLRX – Free Report) to a sell rating in a report published on Tuesday morning. Separately, HC Wainwright reissued a buy rating and issued a $21.00 price objective on shares of BioLineRx in a research note on Wednesday, April 17th. View Our Latest Analysis on BioLineRx BioLineRx Stock Performance NASDAQ:BLRX […]

BioLineRx (NASDAQ:BLRX – Get Free Report) was upgraded by investment analysts at StockNews.com to a “sell” rating in a research report issued to clients and investors on Tuesday. Separately, HC Wainwright reiterated a “buy” rating and set a $21.00 price target on shares of BioLineRx in a report on Wednesday, April 17th. Check Out Our […]

HC Wainwright reaffirmed their buy rating on shares of BioLineRx (NASDAQ:BLRX – Free Report) in a research report report published on Tuesday morning, Benzinga reports. HC Wainwright currently has a $21.00 price target on the biotechnology company’s stock. HC Wainwright also issued estimates for BioLineRx’s Q1 2024 earnings at ($0.29) EPS, Q2 2024 earnings at […]

BioLineRx Ltd. (NASDAQ:BLRX – Get Free Report) was the target of a large growth in short interest in the month of December. As of December 31st, there was short interest totalling 225,200 shares, a growth of 96.2% from the December 15th total of 114,800 shares. Based on an average daily volume of 349,200 shares, the […]

BioLineRx (NASDAQ:BLRX – Get Free Report) and Sonnet BioTherapeutics (NASDAQ:SONN – Get Free Report) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, risk, earnings, valuation and analyst recommendations. Valuation & Earnings This table compares BioLineRx and […]

BioLineRx (NASDAQ:BLRX – Get Free Report) and Sonnet BioTherapeutics (NASDAQ:SONN – Get Free Report) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, risk, analyst recommendations, profitability, valuation and dividends. Analyst Recommendations This is a summary of recent […]

BioLineRx (NASDAQ:BLRX – Get Free Report) was upgraded by investment analysts at StockNews.com to a “sell” rating in a research report issued on Monday. Separately, HC Wainwright restated a “buy” rating and set a $21.00 price objective on shares of BioLineRx in a research report on Monday, November 20th. Check Out Our Latest Analysis on […]

BioLineRx (NASDAQ:BLRX – Get Free Report) announced its earnings results on Monday. The biotechnology company reported ($0.30) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.18) by ($0.12), MarketWatch Earnings reports. During the same period last year, the firm posted ($0.15) EPS. BioLineRx Price Performance BLRX opened at $1.52 on Wednesday. […]

BioLineRx (NASDAQ:BLRX – Get Free Report) announced its earnings results on Monday. The biotechnology company reported ($0.30) EPS for the quarter, missing the consensus estimate of ($0.18) by ($0.12), MarketWatch Earnings reports. During the same period in the previous year, the company earned ($0.15) earnings per share. BioLineRx Price Performance BLRX stock opened at $1.70 […]

BioLineRx Ltd. (NASDAQ:BLRX – Get Free Report) saw a significant drop in short interest during the month of October. As of October 15th, there was short interest totalling 1,030,000 shares, a drop of 59.8% from the September 30th total of 2,560,000 shares. Based on an average daily volume of 1,200,000 shares, the days-to-cover ratio is […]